Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease.

Nobuharu TamakiNagambika MunaganuruJinho JungAed Qas YonanRohan R LoombaRichele BettencourtVeeral AjmeraMark A ValasekCynthia BehlingClaude B SirlinStephen Caldwell

Published in: Gut (2021)

≥30% reduction in MRI-PDFF in early phase trials can provide a useful estimate of odds of ≥1 stage improvement in fibrosis. These data may be helpful in sample size estimation in non-alcoholic steatohepatitis trials.

Keyphrases

liver fibrosis
contrast enhanced
magnetic resonance imaging
diffusion weighted imaging
electronic health record
liver injury
big data
magnetic resonance
drug induced
data analysis